Pluristyx, a leading provider of clinical-grade induced pluripotent stem cell (iPSC) solutions, and Qkine, a pioneer in the manufacture of high-purity, animal-free growth factors and cytokines, today ...

NYBCe and CZ Biohub will derive iPSC lines from cord blood's immune cells, creating shared, broadly compatible resources for cell therapy, disease modelling, and AI-driven drug development.

Trailhead Biosystems, Inc. (TrailBio.com), a biotechnology company advancing human cell innovation, announces the commercial ...

Amsbio has expanded its range of iPSC Differentiation Kits, offering faster and more flexible generation of specific neural ...

iPSC-derived cell models are a widely used tool that enables scientists to generate various cell types, organoids, and tissues. They are also instrumental in creating disease-specific phenotypes using ...

Dr. Finkbeiner provides an overview of advances in the culture of iPSCs and how scientists are using iPSCs to study neurodegenerative diseases like Alzheimer’s, Parkinson’s, Huntington's, and ALS.

Nicola Bevan is a manager in the BioAnalytics Applications Group (Royston, UK) of Sartorius (Göttingen, Germany). Her team is focused on the development of novel applications and delivering ...

A benchtop bioreactor system developed at Hannover Medical School can produce up to 40 million human immune cells per week ...

TOKYO & MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and ...